BCRX · Biocryst Pharmaceuticals Inc
$9.55
-0.11 (-1.14%)
At close · Aug 21
Market Cap
$2.47B
Shares
255.54M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.55
Open$9.67
Day$9.48–9.91
52W close$6.24–11.11
Avg vol 30d3.3M
Short int32.8M · 12.8% float · 12.4d
Short vol32%
Last earningsAug 5, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Oct 25, 2026
Est · unconfirmed
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+13%
above
Price vs 50-day avg
−1%
below
RSI (14)
49
neutral
MACD trend
Positive
52-week position
68%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+2%
trailing
6-month return
+11%
trailing
YTD return
+22%
this year
Relative strength
−1%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +55 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.84% of float · ▲ +5.1% MoM · 12.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
317 holders — near 3-yr high, broad support
Squeeze score
78
high risk · 0–100
Fundamentals
Revenue growth
−4%
Y/Y
EPS growth
+381%
Y/Y
Free cash flow
$347.0M
Balance sheet
$89.7M
net cash
Quant / Vol
risk profile
Volatility
47%
annualized · 1-yr
Max drawdown
−27%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
ORLADEYO revenue
· full year 2026
Initiated
$625M – $645M
Non-GAAP operating expense
· full year 2026
Non-GAAP
Raised
$420M – $440M
Jan 12, 2026
$380M – $390M
changed to
Aug 5, 2026
$420M – $440M
Prior guidance
period ended
· from the 8-K filed Nov 3, 2025
Global net ORLADEYO revenue
· full year 2025
$590M – $600M
Non-GAAP operating expenses, excluding stock-based compensation
· full year 2025
$430M – $440M
Guided vs delivered
· last 1 settled
No less than $320 million
2023
guided at least $320M
$331.41M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+13%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
49
Neutral
MACD trend
Positive
Bullish
52-week position
68%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $10 › 200d $8 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +55 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
12.84% of float · ▲ +5.1% MoM · 12.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
317 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $10 · 68%
Range high $11
vs 200-day avg +13%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP operating profit non-GAAP | $113.2M | the second quarter of 2026 | — |
| ORLADEYO net revenue | $158.2M | FY2026 Q2 | +0.9% |
|
|
|||
| Cash, cash equivalents, restricted cash and investments | $260.8M | as of March 31, 2026 | — |
| Cash, cash equivalents, restricted cash and investments (pro-forma, including net proceeds from | $330.8M | as of March 31, 2026 | — |
| Net cash utilization | $5.4M | Full Year 2025 | — |
| Non-GAAP total revenues non-GAAP | $592.9M | Full Year 2025 | — |
| ORLADEYO net revenue (excluding European ORLADEYO revenue) non-GAAP | $563M | full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BCRX
this stock
Biocryst Pharmaceuticals Inc
|
$2.47B | +22.4% | -4.4% | — | 12.8% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.85B | +16.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.82B | +1.7% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.94B | -2.4% | — | — | 0.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BCRX | -2.0% | +2.3% | +10.7% | +6.4% | +22.4% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +0.0% | -1.1% | -0.5% | +4.3% | +10.6% |
Key facts
CIK
882796
CUSIP
09058V103
13F (30d)
295 filings
289 filers
Visit website
Investor relations